[144] Nektar Therapeutics SEC Filing

Rhea-AI Filing Summary

Form 144 filed for NKTR (Nektar Therapeutics) reports a proposed sale of 6,666 common shares by an insider through Fidelity Brokerage Services on 09/09/2025 on NASDAQ, with an aggregate market value of $311,204.76. The filing lists total shares outstanding as 19,018,573. The shares to be sold match the sum of restricted stock vesting awards acquired between 05/15/2016 and 11/15/2021 that total 6,666 shares and were granted as compensation. The seller is identified as Howard Robin at the provided address. Recent dispositions by the same person in the prior three months total 14,905 shares for gross proceeds of $518,026.81 across four sales dated 08/19/2025 through 09/05/2025. The filing does not include the issuer name, CIK, or certain contact details in the provided text.

Insights

Securities Analyst

TL;DR: Routine insider sale of previously vested restricted stock; size is small relative to outstanding shares.

The filing documents a planned sale of 6,666 common shares by an insider, sourced from restricted stock vesting between 2016 and 2021, and executed via Fidelity on NASDAQ. Recent sales by the same individual total 14,905 shares for $518,026.81, indicating ongoing monetization of previously granted compensation. The proposed sale equals the sum of the listed vested grants, suggesting no new acquisitions tied to this transaction. Relative to 19.0 million shares outstanding, the single proposed sale is immaterial in dilution or market impact. Missing issuer identification and CIK in the provided extract limit cross-checking against public disclosures.

Corporate Governance Expert

TL;DR: Documentation appears compliant with Rule 144; disclosures show compensation-origin shares being sold, not new transfers.

The table shows acquisition by restricted stock vesting and payment characterized as compensation, aligning with common Rule 144 notices that convert previously restricted awards to freely tradable shares. The seller attests to absence of undisclosed material information in the remarks section, which is the standard certification. The filing lacks issuer name and CIK in the supplied text, so confirming filing context against issuer filings is not possible here. From a governance perspective, clustered insider sales over a short period merit monitoring but are not by themselves a material governance event.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	6666	311204.76	19018573	09/09/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/15/2016	Restricted Stock Vesting	Issuer			230	05/15/2016	Compensation
Common	08/15/2016	Restricted Stock Vesting	Issuer			712	08/15/2016	Compensation
Common	11/15/2016	Restricted Stock Vesting	Issuer			353	11/15/2016	Compensation
Common	02/15/2017	Restricted Stock Vesting	Issuer			480	02/15/2017	Compensation
Common	08/15/2019	Restricted Stock Vesting	Issuer			436	08/15/2019	Compensation
Common	08/23/2019	Restricted Stock Vesting	Issuer			2000	08/23/2019	Compensation
Common	11/15/2020	Restricted Stock Vesting	Issuer			777	11/15/2020	Compensation
Common	08/15/2021	Restricted Stock Vesting	Issuer			728	08/15/2021	Compensation
Common	11/15/2021	Restricted Stock Vesting	Issuer			950	11/15/2021	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	08/19/2025	1573	41826.23
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/02/2025	1500	45243.50
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/04/2025	5166	174119.16
Howard Robin 455 Mission Bay Boulevard South San Francisco CA 94158	Common	09/05/2025	6666	256837.92

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)